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priads of time oil Ihe hrun ttwtsp,utt, wzitiog list. 
Meihdr. Sixtylhroc consecutive patients whu spent >6 
mwdhs w the hcntl tnosplunt raitiog list were eaamind. Meam 
(*SD) qe was 93 f 9 years. mtun left wttriruhtr @dun 
bsctiunms I9 + W,nndall werehtkingdigxin und diurvticwd 
wudilvtw rgettts. Putiatts nhu underwnt trunrpluntrtiun dur. 
ing LLc Idluwup pet&l wrr wormed fmm the prctmospluntu. 
Ihat aaatyris, sod their suwi\ol was ~xilmined us port of the 
pustlraasplsntatim phase ol the study. 
&su&. Of the 63 original putirnta ewnined, 26 uodetwnt 
tnmsplsotatk~tt, 10 during inuttvpic ur mechroicul cirwlatuly 
Cwxlusiarrs. Suniro, ofpatients who hare sunircd ~6 maothr 
on the heart tnnsplnnt waiting list is penerelly good. ~tthougb 
henri tmnsplunts,ion did mu, uppear fo wanler additional sunival 
advnntap uwr medical therapy,a large pm~rtion of the patients 
whu undmment rausplan0ltion ww critically ill at the time ul 
tr.tnspkmlu,ion and nould unduubtedly have died of ptqwsive 
heurt fuiturc had they not undernone tmnst&mta,ion. We con- 
clude that heart tran.plantRtia”“should &I be considered B 
lherapeutic &xnatirs io putitnts with heart &dture veu sner a 
pndougwi wiling ptiud un the heart ttansplunt nailing list. 
Despite rewnt advances in the m;mqrmcnt of cordiuwscular 
disc&e, heat, failure remains 3 sign&ant suurcc of mortality 
and marbidiw. Accordiita to National Hcan, Lune. and Bkwd 
Institute stat&. -7lk$Xl new cubes an; diagnosed rach 
year. and >I million hospital admissions utr rcquircd each 
year because of heart failure. In sdditiun. with the unguing 
impmvemcnts in cardiac intensive care in general and the 
manapment of acute myucrrdial infxctiur in particular. it is 
likely that incrc&ing numhen of patienlr will survive ucutr 
cardiac events only to experience the ongoing murbidity and 
eventual mortality usscciated with chronic cardiac dyrfunctiun. 
Earlier observations (1.2) described an extremely poor pmg- 
nusib ihl patients with left wntricular systolic dysfunction, 
reporting a mortality rate as high as 50% at I year of follow-up. 
Howcvcr. with the advent of angiotensin~nvening enzyme 
inhihtor therapy. the pmgttosis has impmved matkedly. Cohn et 
al. (3) rcpmted a 12.month mortality mte of only 9% in patients 
with chronic mild tu moderate heart failure treated with digitalis, 
diuretic drugs and angiotensin.convcning enzyme inhibitor ibeer- 
spy. Even patients with clinically sewe heat Mm derke a 
decided he&t from angioteosin-mnverting enzyme inhibitor 
therapy. The CONSfiNSUS Trial Study Gmup (4) repotted a 
mon&y mtc after 1 year of 36% in pad&with New York 
Heart Am&ion functional class N heart failure rcceivin~ 
conventional therapy plus angiatcnsin-converting e zyme inhibi- 
ton compared with 52% in patients treated without angiotensin- 
converting enzyme inhibitors 
Meanwhde. during ths late 1980s. heart tmnsplantation 
emcrgcd as ad&able therapeutic okemotive formnnagement of 
severe heart failure. The widzsprcad USC of cyclosporine-based 
immunosuppressive therapy has resulted in I- and 3year past- 
ttnnsplantation sutvival rates approaching 90% and 70%. rcspec- 
tively (5). Unfortunately, with increasing pasttransplantation SW 
viwl have come reports :i ::!z::d conditions, Including al!n@t 
coronary arteriopathy and msttraaplcotation iymphoprolifcra- 
tivc disease, that may evenually prow to be tbc major limiting 
factors in suwival after beat tramplaotation. The5c obscrvatioos, 
coupled with improvementi io heat failure managemcnf have 
raised concerns regarding the optimal timing of heart tramplan- 
tation in patients with sewrc chronic heart failure. SOme b~csti- 
gators (6) have juge<ted that die survival benefit enjoyed atlcr 
heart transplantation IS diminished in patients who spend an 
extended period of dme on the waiti.lg list before tmosplaotation, 
possibly kcaw of se!f-sekction as those who are either able to 
intrinsically adapt to chrukaliy impaired cardiac performance or 
prove particularly rcspunsivc to medical therapy, or WI. We 
sought spaiS& to excmine thin issoc by evaluating clmicai 
ootcomcs in patients with chmxic end-stage heart failure who 
spent >6 months on tbe heart transplant !vaiting list at our 
institution. 
Methods 
Palicntc. Bctwcen January I, 1787, and September 1,1771, 
402 patients were cvaluatcd, and 181 patients with end-stage 
heart failure were accepted as cardiac transplantation candi- 
dates at Loyola University Medical Center. Criteria for accep. 
tancc B a &ndidate for &ansplantation included szvcrc he&t 
failure ffunctionai elm 111 or IV) that was uoorlv controlled 
dcspite’maximal medical therapy.‘Patients v&c f;ee 01 other 
significant medical diseases or irreversible sequelac of chronic 
heart failure. At 6.month follow-up, 29 of the original 181 
candidates had died (16%) after a mean (ZSD) follow-up 
period of 63 2 53 days (mange 2 to 154). II doing inotropic or 
mechanical circulatory support. and 71 had L ridergone heart 
transplantation. A total of 76 patients eventually undetwent 
transplantation with a mean waiting time before tranrplanta- 
tion of 219 2 273 days (median 98). An additional 18 were 
removed from the waiting list before spending 6 months 
waiting, generally for development of a contraindication to 
heart transplantation or clinical improvement to the point 
where hart transplantation was no longer indicated. Thus. of 
the 181 patients who wcrc originally listed as candidates for 
heart transplantation, 63 spent >6 months on the waiting list 
and constitute the study group for this investigation. 
Mean age at the time of listing was 53 ? 9 years, left 
ventricular ejection fraction was 19 Z 6% and exercise toler- 
ance IO.2 2 3.8 min on a modified Naughton treadmill 
protocol. Ail WPK receiving digitalis and diuretic and w&i- 
lator agents. with 92% receiving angiotensin.convcrting cn- 
zyme inhibitors and 52% receiving two or more vasodilai;or 
agents. Vasodilator dose was progressively increased doring 
the followup period, limited by symptoms of lightheadedness. 
worsening angina, cough or increase in serum orca nitrogen or 
crcatinine. Patients in whom fluid overload, prerenal azotemia 
or other end-organ malperfusion or severely symptomatic 
pulmonary congestion could not be prevented with oral med- 
ications or clinically dictated parenteral diuretic drugs received 
inotropic support, either ternporrrily or long term. 
During the follmv-up period, patiertts were seen by a 
physicim! on the Heart Transplant and Cardiomyopathy Scr- 
vice no less frequently than every 4 to 6 weeks. Follow-uo right 
heart catheterization was pcrformcd every 3 to 6 months or 
less, as dictated by the individual patient’s clinical coome and 
baseline central hemodynamic status. Patients were removed 
from the waiting list at the time of death, heart transplantation. 
bcwtsc of clinical improvement to a point where their mndi- 
tion ws judged no longer to require heart transplant or 
because of incidence of a condition that would preclude 
transplantation. 
Statistlccl nastysis Patients were included in the study 
group only after spending 6 months on the heart transplant 
waitiw list. No events occurrinp before the 6.month milestone 
were considered in this analyst. Mortality is dewibed using 
Kaplan-Meier evertt analysis and is expressed using the 
&month milestone BE the zero time point, that is, mortality 
after 6 months of waiting on the heart transplant list. Patients 
who underwent heart tmnsplantation after waiting 26 months 
were censored at the time of transplantation, as were patients 
who were electively taken oU the list. Ltccausc several of the 
patients who underwent transplantation required inatropic 
support at the time ofoperation (andthus hada higher priority 
status for donor matching), their censoring by virtue of trans- 
plantation was clearly not rat&m. To allow for :he near 
certainty that these patients would have died withour rhe 
heightened priority status (thereby reducing group sttnival). 
mortality ws also calculated on the basis of the awmptian 
that all would have died while still waiting 3 months after the 
date of their “priority-assisted” transplantation. These mortal- 
ity rates after the bmonth milestone were calcolatsd and then 
comparedwith the posttransplant mortality rates in all patients 
who underwent heart transplantation after wait;ng 56 months 
on the heart transplant waiting list. 
For the study 63 patients, the overall pretmnsplnnt mortal- 
ity rate (Fig. Ii wai 6% after 6 month; (total of 12 months 
swat on the waitine list). 12% after 12 months (total of 18 
iaoths) and 22% o;er 1s months (total of 24 mon‘ths). There 
were a tolal of scvc” deaths, two sudden and unexpected and 
five from pmgrcssive heart failure. All patients were main- 
tained with vmodilatcr agents (usually angioteosinsonvcrtirtg 
enzyme inhibitors), aed 36 (57%) of the 63 were receiving two 
or more different vasodilator preparations. Of these 63 pa. 
tients, 25 cventualiy underwent heart transplantation with a 
mean pretransplantalion waiting period after the bmonth 
milestone of8.24 t 6.91 months (251 2 210 days). At the time 
of heart transplantation, 10 (40%) of 25 had progressed to 
requiring inolropic support with dobutamine (mean dosc 5.3 Z 
1.8 wkg body weight per ruin, raw 2.5 to IO), and 2 had 
intrr&r& b&on &ip support as-well. The p&ransplrm- 
tation actuarial survival rate (Fig. I) was 5% at 6 months, 10% 
at I2 months and 24% at 18 months. There was no difference 
in survival between the observed pretr.~nsplantation and post- 
transplantation survival at any time durinp the 18.month &dy 
oeriod. When the IO oatientswith inotroolc swmort nt the time 
bf transp!antation were assumed to l&e htd (whi!e still 
awaiting heart transplantation) 3months after the dnte of their 
actual heart transplantation. the overall pretransplantation 
(i.e., heart failurej mortality rate incrcasdd to IS& after 6 
months and 35% after I2 months. This survival ewe lies 
predominantly outsick the limits of the 95% confidewe inter- 
val for the observed pretransplantation suwival rate (Fig. 2). 
Discussion 
The present study demonstrates that the ongoing mortality 
rate after 6 months on the heart transplant waiting list without 
transplantation is similar to the postoperative mortality eape- 
tieneed by patients who undergo transplantation after waiting 
>6 months. 
“pi-e 2. Ottned ~ctuari~t sulvival rate of padena 
beginning after a bmonth wait an the heart ransplant 
waitinnlii foatients cawed at time of tmmn~anrarionl 
comp&d w’ith hypothetic mortality of psi&s during 
the same period. assuming morlality of all patlrms who 
underwent pd-xitized heart rramplanlaliorl 3 months 
after the date of sansplantation from heart failure 
without (w,ol reXYE tramplantation. 
Prioritiaed hwrt transplantation. With recent advances in 
Ihe mcdiral omnagement of chronic heart failure. the progno- 
sis for such pirtients has much improved. Patients with noder- 
ate disease have the potential for excellent survival (3), and 
even pntients with advanced isease can have reasonable hope 
for it least 6 to I?-month survival (4). Indeed, previous 
ohsrlvations (6) have swested that after -8 months on the 
waiting !ist. the survival-Genefit associated with heart tr(ms- 
plantation is minimal (6). Our study seems to confirm that 
patients who have waited 26 months on the heart transplant 
waiting list do not, as B group. de& a significant survival 
benefit from heart transplantation. However, closer scrutiny 
reve& tnat a large proportion of those patientswho eventually 
undewent transplantation after a 6-month waif had experi- 
enmd progression of disease to the point where they were 
inotrope dependent for maintenance of renal perfusion, he- 
modynamic stability or symptomatic relief and were therefore 
placed at a high priority status for heart transplantation. It is 
likely that the mortality among this subgroup aoold have been 
extremely high had they oat uildergone heart transplantation, 
because patients who require ongoing inotropic circolstoty 
support generally have a poor prognosis. When the ability to 
prioritize selectively for transplantation on the hasis of clinical 
stotos, that is, biased censoring, was eliminated by assigning the 
patients who received “prioritized transplants” to death 3 
months later, the mortality does differ from the observed 
“medical” survival. 
Pmgoosticalioo In heart failure. Many patients with ex- 
tremely poor ventricular function remain well compensated for 
extended periods of time. Unfortunately, it remains extremely 
difficult to predict clinical deterioration in patients with heart 
failure. Peripheral adaptive mechanisms may allow for a 
relatively unimpaired but borderline patient at baseline with 
minimal cardiac resew who is susceptible to rapid deterioraa- 
tion with any additional carri;oc perturbation, such as atrial 
fibrillation or ventricular dilation with mitral regurgitation. 
This is particularly true for patients with were chrooic heart 
failure receiving optimized vascdilator therapy. In such cases, 
standard variables, such os ejection fraction. central hcmody- 
namic measurements and even exercise tolerance. may not 
enable clinicians to identify, with tbe requisite degree of 
certainty, those patients who should or should not continue as 
active candidates for heart transplantation after 6 months uo 
the waiting list. Individual variables have been shown to have 
prognostic value (7-10). Unfortunately, patients may exhibit 
conflicting features, some of which p&end a good prognosis 
and others a paorer one. 
In such a setting, determination of ao overall prognosir in 
on effort to establish candidacy for transplantation may prove 
extremely difficolt. This is of particular impmtsoce in the 
current era of scarce donor organs and an ever.increring 
waiting period. even for high priority patients. Many can 
anticipate o wait of a6 months before oo appropriate donor 
organ can be identified (11). l%oa. when deciding whether to 
place a patient on the heart transplant waiting list, the clinician 
most attempt not only to ascertain how well the patient’s 
clinical status may be optimized with conventional therapy, 
medical or sorgicol. hot also to predict the overall course over 
the subsequent 6 to I2 months or even longer. 
%gan riiocaliun. Ironically, the extended sorvival that 
identifies certain patients os those who may benefit less from 
trousplantation also gradually increases their priority for trans- 
plantation 8s they accroe more waiting time on the list. 
Although their relatively well comlwxated clinical status at 
the time of heart transplantation is associated with better 
outcome (United Network for Organ Shoring [UNOSj Scien- 
tific Registry 8s of November IW2), these patients may 
actually be diverting a portion of the already scarce donor 
organ pool from more criticolly ill patients in the early stages 
of waiting who may not survive long enough for heart trans- 
plantation to be performed. Stevenson et al. (6) have adve- 
cated critical reassessment of t:aosplantation candidacy if a 
patient sotvives for >6 months while awaiting heart transplan- 
tation. A possible extensioo of this approach would be to 
pe~lorm heart transplantation in patients waiting >6 months 
only if the hemadynamic, arrhythmic or functional status 
suggests ao extremely poor short-term prognosis, such as 
inotiope dependence, recurrent ventricular arrhythmias with 
associated hemodynamic embarrassmmt or severely ,mpaired 
exercise tolerance. lo oar cohoti, there were 0x1~ 2 patients 
who died unexpectedly among the 63 patients in the stody 
group, which xcorred ot 10 and 18 mo:ths after listing 8s 
candidates for transplantation. Consequently. in the majority 
of instances, mortality could he anticipated, and interventions. 
medical or mechanical, mulo be instituted, including reinstatc- 
meet on the active heart transplant waiting list with a high 
priority. This approach would tend to shift at least a pation of 
the available donor organs to patients in the arty course of the 
waiting period, thus maximizing the sheox that critically ill 
patients receive a donor heart in relatively short urder. With 
the current shortage in donor organs, even patients who have 
the highest priority under UNOS guidelines -:ao expect !o wait 
for an extended period of time before a donor organ is 
identified. 
Study limhtioos. By its natow, o study of this rype is 
highly dependent on the individual practice patterns of the 
clinicians invoixd. Even among professional owxiates, clini- 
cal decision making often varies sianificantly. lhis is ranico- 
lady tree in cases-of patients with chrooif heart f&re. in 
whom obiective findines tow be krs helofol than in the acute 
phase of ihc diseax (Ii), atth there is an’increased reliance on 
subtle historical data. In particolar, decisions mttecrning the 
initiation of inotropic or mechanical circolatoty support coo 
potentially iofloenee outcome. particularly in patients with 
heart failure on the transplant waiting list. There are very few 
controlled observations describing the effects of iwtropic 
agents on sowivol in these patients, and thus the use of these 
medications in the mmagemnt of chronic heart failure R- 
mains somewhat controversial (I3-IS). Tbae ittterventiow 
have the additional effect of increasing the tr;msplantatiun 
priority of the individual in whom they are used, forther 
confounding the assessment of their ellcczs on prognosis, 
particularly in ptients awaiting transplantation. Vasodililtor 
agents, particularly angiotensin-eonuerting cnryme inhibitor% 
are now kown to improve prognosis in patients with heart 
failure (3,4,16), hot titration of these agents to achieve optimal 
dosing cat be inconsistent (!7). Other mrosoreg such os the 
use of betaadrenergic antagonists- have shown potential ben- 
efit (la), but their role in the rootinc care of patients with 
severe hart failure has yet to be determined. 
Conclusiens. Patients with severe heart failore who haw 
sowived >6 months awaiting heart transplantation have a 
generally gaad short-term prognosis regordlers of whether they 
undergo lransplantation or not. However, this equity of SOT- 
viva1 may be related to the selective prioritiration of clinically 
decompasated patients fur heart transplantation in thesr 
patients, iodividoai patient risk stratification. particularly long 
term, can be difficult. lo view of this uncertainty. heart 
transplantation should cootinoe to he performed in peiexs 
waiting 26 months with ongoing critica! assessment of the 
risk/benefit ratio for this proceda:e. 

